Compugen Ltd. (NASDAQ:CGEN) – Stock analysts at Oppenheimer cut their FY2018 earnings estimates for shares of Compugen in a report released on Wednesday, November 7th, Zacks Investment Research reports. Oppenheimer analyst M. Breidenbach now forecasts that the biotechnology company will post earnings of ($0.43) per share for the year, down from their previous forecast of ($0.41). Oppenheimer currently has a “Buy” rating and a $9.00 target price on the stock. Oppenheimer also issued estimates for Compugen’s Q3 2019 earnings at ($0.17) EPS, Q4 2019 earnings at ($0.16) EPS, FY2019 earnings at ($0.68) EPS, FY2020 earnings at ($0.66) EPS, FY2021 earnings at ($0.72) EPS and FY2022 earnings at ($0.73) EPS.
Separately, Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a report on Tuesday, October 16th.
Compugen (NASDAQ:CGEN) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.07. The business had revenue of $7.80 million for the quarter, compared to analyst estimates of $7.80 million.
A number of hedge funds have recently added to or reduced their stakes in CGEN. Commonwealth Equity Services LLC bought a new stake in Compugen during the second quarter valued at about $106,000. Jane Street Group LLC bought a new stake in Compugen during the third quarter valued at about $128,000. Aviance Capital Management LLC bought a new stake in Compugen during the third quarter valued at about $151,000. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Compugen by 34.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 167,600 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 42,900 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Compugen by 8.2% in the third quarter. Renaissance Technologies LLC now owns 265,100 shares of the biotechnology company’s stock valued at $1,021,000 after buying an additional 20,200 shares during the period. Institutional investors own 21.68% of the company’s stock.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.